Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2206 studies found for:    ovarian cancer
Show Display Options
Rank Status Study
21 Terminated Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab;   Drug: Revlimid, Doxil, Avastin
22 Terminated
Has Results
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
Conditions: Cancer;   Neuroendocrine;   Ovarian Cancer;   Colon Cancer
Interventions: Drug: JI-101;   Drug: Everolimus
23 Completed Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study
Condition: Ovarian Cancer
Intervention: Procedure: DCE-MRI scans
24 Recruiting Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer at Low Genetic Risk
Conditions: Ovarian Cancer;   Breast Cancer
Intervention: Drug: LY2606368
25 Recruiting Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Procedure: ovarian cancer surgery
26 Active, not recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Intervention: Drug: AZ2281 + Carboplatin
27 Not yet recruiting BRCA-Screening in Ovarian Cancer
Conditions: BRCA Status;   Ovarian Cancer
Intervention: Genetic: Testing of BRCA status regarding germline and somatic mutation
28 Active, not recruiting Chemotherapy-Related Toxicities In Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Behavioral: Interview;   Behavioral: Questionnaire
29 Terminated Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Procedure: Seprafilm™
30 Active, not recruiting M. D. Anderson Symptom Inventory - Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Behavioral: Interview;   Behavioral: Survey
31 Completed Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Genetic: protein expression analysis;   Other: immunohistochemistry
32 Recruiting First Line Ovarian Cancer Treatment - Cohort Study
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Bevacizumab
33 Active, not recruiting Sexual Functioning After Primary Treatment of Ovarian Cancer
Conditions: Ovarian Cancer;   Sexual Dysfunction
Intervention: Behavioral: questionnaires
34 Unknown  Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis
Conditions: Ovarian Cancer;   Peritoneal Metastasis
Intervention: Procedure: intravenous contrast administration
35 Completed
Has Results
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: imatinib mesylate by mouth;   Drug: Gemcitabine Intravenous
36 Recruiting Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Conditions: Ovarian Diseases;   Ovarian Neoplasms
Interventions: Other: Laboratory Tumor Marker Analysis;   Other: Transvaginal Ultrasound;   Other: Health Status Questionnaire
37 Not yet recruiting Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Nuc-1031 and Carboplatin
38 Withdrawn CA-125 in Screening Patients at High Risk for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Other: physiologic testing;   Procedure: study of high risk factors
39 Active, not recruiting
Has Results
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281
40 Withdrawn Cost Utility Analysis in Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years